Klarna has fallen roughly 75% from its post-IPO high, yet revenue rose 27%, transaction margin dollars surged 42%, and co-founder/CEO Sebastian Siemiatkowski just bought $9.95 million of KLAR. Is Wall Street pricing a broken fintech—or overlooking a rapidly evolving payments platform?

Read entire article

DICK’S Sporting Goods plunged roughly 30% as Foot Locker weakness rattled Wall Street. Then three directors bought $2.94 million. With core DICK’S comps up 4.9%, operating cash flow at $792 million and the stock at 9.3x forward earnings, is Wall Street pricing temporary integration pain like permanent deterioration?

Read entire article

NGL Energy Partners director John Raymond just put $5.1 million behind the turnaround. With record Permian water volumes, rising EBITDA and heavy institutional ownership, NGL looks increasingly compelling—but leverage keeps our FunStock Index at 7.95/10.

Read entire article

Kura Oncology is evolving from a clinical-stage biotech into a commercial oncology company. With KOMZIFTI gaining traction, over $500 million in cash, strong institutional ownership and multiple Phase 3 catalysts ahead, is KURA becoming one of biotech's most compelling long-term opportunities?

Read entire article

A 94x P/E usually screams "expensive." Alaska Air may be the exception. With a 0.31x Price-to-Sales ratio, a $1 million CEO purchase, 95% institutional ownership, and major Hawaiian Airlines synergies ahead, the market could be misreading today's earnings power.

Read entire article

Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?

Read entire article

Medifast (NYSE: MED) has nearly $170 million in cash, no debt, insider buying and a bold strategic pivot through Trilivy. But shrinking revenues and GLP-1 competition still cast a long shadow. Here's the complete bull vs. bear case.

Read entire article

Primo Brands isn't simply selling bottled water.

It's quietly building one of North America's largest hydration infrastructure platforms.

With repeat CEO insider buying, nearly $800 million in annual free cash flow, raised guidance, and exceptional institutional ownership, PRMB deserves a closer look.

Read entire article

Intel finally looks like a company moving in the right direction. AI demand is accelerating, the balance sheet is stronger, Intel Foundry could reshape the company's future, and CEO Lip-Bu Tan is buying shares alongside investors. The turnaround appears increasingly credible. The valuation? That's where patience may still pay.

Read entire article

Artificial intelligence doesn't just require better chips—it requires vastly more electricity. Ameresco sits at the intersection of AI infrastructure, energy modernization, and microgrids, backed by a record $6.73 billion backlog, significant insider buying, and improving operational momentum. The opportunity is compelling, but so are the risks.

Read entire article